WIV

Focusing on the development of BsAbs in China, YZY Biopharma Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Wednesday, September 13, 2023
Bispecific monoclonal antibody, Malignant pleural effusion, GMP, Antigen, YZY, International, Paracentesis, Epithelial cell adhesion molecule, CD3, CMC, Cancer, Ageing, Haemophilia, Pleural cavity, Stock exchange, CSPC, Peritoneum, Research, Immunotherapy, Shijiazhuang Pharma Group, MPE, Motherboard, Patient, Ophthalmology, SEHK, MA, TME, WIV, Immune system, Epitope, Tumor microenvironment, Ascites, Property management, Vaccine, Fine chemical, Pharmaceutical industry, PRC

The Company carefully selects potential targets for its BsAbs, and has adopted a differentiated clinical development strategy to maximize the clinical and commercial value of its drug candidates.

Key Points: 
  • The Company carefully selects potential targets for its BsAbs, and has adopted a differentiated clinical development strategy to maximize the clinical and commercial value of its drug candidates.
  • Since its establishment, YZY Biopharma focuses on the development of BsAbs in China.
  • In addition, the Company is also focusing on the development of the TME-targeted BsAbs, including Y101D and Y332.
  • Therefore, the execution of an appropriate CMC development strategy is vital to the success of the overall drug development program.

PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

Retrieved on: 
Tuesday, December 20, 2022
Hospital, Severe acute respiratory syndrome coronavirus 2, Ritonavir, Neuropsychiatric Disease and Treatment, SIMM, Chinese Academy of Sciences, Patient, National Medical Products Administration, Trial of the century, Clinical trial, Central nervous system, Phase, Simcere Pharmaceutical, Drug discovery, Biotechnology, Capacity building, Fatality, Health, Degenerative disease, III, China-Japan Friendship Hospital, COVID-19, Medicine, Technology transfer, Safety, Post-exposure prophylaxis, National Center for Advancing Translational Sciences, Peking Union Medical College, Infection, Wuhan Institute of Virology, WIV, Cancer, NDA, Fear, FPI, Viral load, New Drug Application, Wuhan Jinyintan Hospital, Research, CAS, Pharmaceutical industry, Materia medica, Study, Virology

Simcere will accelerate the analysis of clinical study results and actively prepare for New Drug Application (NDA), while speeding up the expansion of production capacity to meet urgent clinical needs.

Key Points: 
  • Simcere will accelerate the analysis of clinical study results and actively prepare for New Drug Application (NDA), while speeding up the expansion of production capacity to meet urgent clinical needs.
  • This is to fulfill the Group's corporate mission of "providing today's patients with medicines of the future".
  • The Study has established a total of 43 clinical research centers in 20 provinces, municipalities and autonomous regions in China.
  • XIANNUOXIN is a combination packaged drug of a small molecule anti- SARS-CoV-2 drug candidate and Ritonavir, this candidate is targeted 3CL protease which is essential for SARS-CoV-2 viral replication.

A statement from AK Consulting and Trans on The COVID-19 Lab Leak - Hypothesis: A Reasonable Suspicion or Conspiracy Theory?

Retrieved on: 
Friday, September 10, 2021

Since all hypotheses remain open and require further study, why are those people eager to spread unidentified information on the Internet?

Key Points: 
  • Since all hypotheses remain open and require further study, why are those people eager to spread unidentified information on the Internet?
  • Is it really a reasonable suspicion, or just a conspiracy theory used by some people who have ulterior motives to spread rumors?
  • When you deal with Fox News and Global Times, you can hardly see the difference, for they all point fingers at Fort Detrick.
  • Hyping up the Lab Leak Theory in the U.S. as an attempt to falsely blame China.

New Research Demonstrates Claims that the Wuhan Institute of Virology had no cases of COVID-19 are not credible

Retrieved on: 
Thursday, May 27, 2021
Health sciences, Health, WIV, Food and Drug Administration, Pharmaceutical industry, COVID-19

An island of uninfected people at the WIV could not have existed in Wuhan at that time."

Key Points: 
  • An island of uninfected people at the WIV could not have existed in Wuhan at that time."
  • "This study cannot address directly the timing of early cases," continued Mr. Demaneuf.
  • He holds 87 US patents and has invented seven FDA-approved pharmaceuticals which have helped over 80 million people.
  • He is the author of the best-selling book on surviving the pandemic, Stay Safe: A Physician's Guide to Survive Coronavirus, available here .

New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus Pandemic

Retrieved on: 
Wednesday, October 28, 2020
Animal virology, Coronavirus, WIV, COVID-19 pandemic in mainland China, Draft:Misinformation related to the COVID-19 pandemic - restructure

The paper documents four patients from the PLA Hospital that have the earliest genetic signature of direct human-to-human coronavirus transmission.

Key Points: 
  • The paper documents four patients from the PLA Hospital that have the earliest genetic signature of direct human-to-human coronavirus transmission.
  • The PLA Hospital is three km from WIV and both are located on Line 2 of the Wuhan Metro System.
  • Line 2 also services the Hunan Seafood Market, previously suggested to be associated with the origin of the pandemic.
  • He is the author of the best-selling book on surviving the pandemic, Stay Safe: A Physician's Guide to Survive Coronavirus.